Isosorbide dinitrate (oral formulations) Review

How isosorbide dinitrate works

Isosorbide dinitrate belongs to the nitrate class of medicines and works by relaxing blood vessels, which increases blood and oxygen supply to the heart and reduces the heart's workload. This vasodilatory mechanism underlies its use to prevent angina caused by coronary artery disease.

Because the effect is systemic vasodilation, the clinical benefit is prevention of angina episodes when used regularly; the drug does not reliably relieve an established angina attack unless the sublingual formulation is used as directed.

Available oral and sublingual formulations

Oral immediate‑release tablets are available in 5 mg, 10 mg, 20 mg, 30 mg and 40 mg strengths; a 40 mg extended‑release (ER) tablet is also marketed. A sublingual tablet formulation exists and, per product guidance, is the only form recommended to treat an active angina attack.

Regular (immediate‑release) and extended‑release oral tablets are indicated for prevention of angina on a chronic basis and will not treat an angina attack that has already begun; patients should be instructed on which formulation they have and how to use the sublingual tablet for acute symptoms.

Common and serious adverse effects to expect

The most commonly reported adverse events across patient information sources are headache and dizziness. Headaches can be severe; web and drug reference sources list headache and dizziness as the leading side effects patients report while taking isosorbide dinitrate.

More serious reactions requiring clinician attention include symptomatic low blood pressure (light‑headedness or fainting), fast or slow heart rate, palpitations, worsening angina, and allergic reactions (hives, facial or throat swelling, difficulty breathing). Patients experiencing severe light‑headedness or syncope should seek immediate care.

When isosorbide dinitrate should and shouldn't be used

Isosorbide dinitrate is prescribed only by a clinician; it is intended for patients with angina to prevent episodes when taken regularly. Only the sublingual tablet is appropriate for treating an acute angina attack—regular and ER tablets will not provide the rapid relief needed for a started attack.

Pediatric safety and efficacy have not been established: appropriate studies in children have not been performed, and labeling indicates safety and efficacy are not defined in the pediatric population.

Practical prescribing and patient counseling notes

Patients should be told that headaches and light‑headedness are common, and to sit or lie down if they feel faint. They should understand which formulation they have (immediate release, ER or sublingual) and that only the sublingual tablet should be used for an acute attack.

Storage guidance from clinical references recommends keeping tablets at room temperature in a dry place; patients should follow prescribing clinician and pharmacist instructions and report severe adverse events such as syncope, palpitations or signs of allergy.

Pros & Cons

• ✅ Available in multiple oral strengths (5 mg, 10 mg, 20 mg, 30 mg, 40 mg) plus a 40 mg extended‑release tablet, allowing dose titration
• ✅ Sublingual tablet formulation is available and is the recommended form for treating an active angina attack
• ✅ Mechanism reliably relaxes blood vessels to increase cardiac oxygen supply and reduce workload—established pharmacologic approach for angina prevention
• ✅ Clear labeling distinguishes preventive use (regular/ER tablets) from acute treatment (sublingual), simplifying patient counseling

• ❌ Severe headache is a common adverse effect and is frequently reported in clinical information sources
• ❌ Can cause symptomatic low blood pressure (light‑headedness, fainting) and dizziness—may limit use in susceptible patients
• ❌ Potential for cardiac-related adverse effects reported (worsening angina, abnormal heart rate or palpitations) that require prompt medical review
• ❌ Prescription-only medication requiring clinician oversight; pediatric safety and efficacy have not been established

How It Compares to the Competition

• Isordil (brand) — A widely marketed immediate‑release isosorbide dinitrate brand with the same indications and similar dosing options.
• Dilatrate‑SR — A branded isosorbide dinitrate formulation listed in product references; serves the same antianginal prevention role.
• Isochron / IsoDitrate — Other trade names under which isosorbide dinitrate is sold; comparable indications and safety profile.
• Apo‑ISDN (Canada) — Canadian marketed isosorbide dinitrate product with equivalent antianginal use as documented in clinical references.

Who Should Buy This & Who Should Skip It

Buy it if: Patients with recurrent angina who need a preventive antianginal and can tolerate systemic vasodilation are appropriate candidates when prescribed by a clinician. Individuals who require a sublingual option for acute attacks should confirm they have the sublingual tablet and understand its use.

Skip it if: People prone to symptomatic low blood pressure, frequent severe headaches, or those without access to physician follow‑up would be better served by alternative angina strategies under clinician advice. Pediatric patients should avoid use unless a specialist provides specific guidance, as safety and efficacy in children are not established.